Evaluating Efficacy of Antiseptic Mouth Rinses on Salivary SARS-CoV-2 Infectivity

摘要 评价市售消毒液对SARS-CoV-2感染性的抗病毒效果 迅速减少病毒传播的巨大潜力，特别是在新毒株出现的情况下。鉴于SARS- CoV-2主要通过气雾剂、唾液和呼吸道分泌物传播，以减少病毒 负担是一种有吸引力的减少传播的方法；对于牙科和其他医疗保健尤其如此 设置有大量病人，需要在非常接近头部和颈部的地方工作，并生成 程序性气雾剂。尽管研究表明，一些消毒液具有抗病毒作用。 在体外抗SARS-CoV-2和体内其他包膜病毒的特性，近年来仍有数据涌现 随机临床试验(RCT)，包括我们在亚当斯牙科学院的试验，关于防腐剂是否 漱口水在体内可以减少SARS-CoV-2病毒的感染。为了解决这一知识差距，我们建议确定是否 含乙醇、过氧化氢、聚维酮碘、洗必泰或氯化十六烷基吡啶的漱口水 降低SARS-CoV-2病毒载量、复制和传染性(目标1)，并表征唾液炎性和 用唾液样本检测早期SARS-CoV-2感染相关抗体反应(AIM 2) 我们最近的新冠肺炎患者随机对照试验。总之，从这些目标产生的数据将证明 消毒漱口水可降低唾液中的SARS-CoV-2病毒载量和传染性，并将成为局部的特征 口腔对SARS-CoV-2的炎症反应，最终目标是限制病毒传播。这些 研究将产生数据，以开发可行、廉价、可快速实施的协议，以缓解 预防和控制SARS-CoV-2的传播，解决这一紧迫的公共卫生需求，产生广泛的翻译影响。我们的 跨学科团队是唯一有资格执行拟议工作的团队，因为我们拥有创新的 方法、BLS2设备、SARS-CoV-2样本和实现我们目标的专业知识。此应用程序 包括跨多个学科的资深和初级教员之间的协作，以确保严谨和 我们研究结果的可译性。

ABSTRACT Evaluating the antiviral potential of widely available commercial antiseptic rinses on SARS-CoV-2 infectivity holds great potential for rapidly reducing viral transmission, particularly as novel strains emerge. Given that SARS- CoV-2 is transmitted primarily through aerosols and salivary and respiratory secretions, strategies to reduce viral burden is an attractive approach to mitigating spread; this is particularly true for dental and other healthcare settings which have high patient volumes, require work in close proximity to the head and neck, and generate procedural aerosols. Though studies have demonstrated that some antiseptic mouth rinses have antiviral properties against SARS-CoV-2 in vitro and other enveloped viruses in vivo, data are still emerging from recent randomized clinical trials (RCT), including ours at the Adams School of Dentistry, regarding whether antiseptic mouth rinses reduce SARS-CoV-2 in vivo. To address this gap in knowledge, we propose to determine whether mouth rinses containing ethanol, hydrogen peroxide, povidone-iodine, chlorhexidine, or cetylpyridinium chloride reduce SARS-CoV-2 viral load, replication and infectivity (Aim 1) and to characterize salivary inflammatory and antibody responses associated with early SARS-CoV-2 infection (Aim 2) using salivary samples derived from our recent COVID-19+ patient RCT. Altogether, the data generated from these aims will demonstrate whether antiseptic rinses reduce salivary SARS-CoV-2 viral load and infectivity, and will characterize the local inflammatory response to SARS-CoV-2 in the oral cavity with the ultimate goal of limiting viral spread. These studies will generate data to develop feasible, inexpensive, rapidly implementable protocols to mitigate the spread of SARS-CoV-2 and address this urgent public health need with broad translational impact. Our interdisciplinary team is uniquely qualified to conduct the proposed work as we have the innovative methodologies, BLS2+ facilities, SARS-CoV-2+ samples, and expertise to achieve our aims. This application includes collaboration between experienced and junior faculty across multiple disciplines to ensure the rigor and translatability of our findings.